We are keen to hear from Bioinformaticians and Data Scientists with a proven track record in applying genomics and biomedical dataset analysis to support late stage drug discovery and clinical trial design. You will join the Portfolio Delivery team and the Biomedical Informatics department, working as part of a cross-functional team dedicated to the application of BenevolentAI’s data integration and precision medicine activities to our drug discovery programmes.
The Portfolio Delivery team helps ensure our internal analysis tools and algorithms, as well as our data, are used to their fullest extent in our drug discovery programs. It helps structure our drug discovery workflows and devises new computational approaches to help answer biological questions raised by our various disease programs, for example to support the identification of biomarkers.
As an Advanced Bioinformatics Data Scientist in the team, you will contribute to this challenge with your technical, data analysis, and biological knowledge, providing technical expertise to our drug discovery teams in the discovery and clinical development of targets. In that process, you will identify and implement new methodologies that can make their ways into our standard products, therefore contributing to the growth of our abilities as a company.
Responsibilities
- Applying the Benevolent Platform to generate biological insights that lead to testable hypotheses relevant to Drug Discovery and Clinical Development programmes undertaken by BenevolentAI.
- Developing programmatic tools and workflows that enable the analysis of biomedical datasets.
- Working as a member of a cross-functional team that brings together the best in class Informatics, Drug Discovery and Translational Medicine capabilities to tackle the scientific challenges BenevolentAI is looking to find solutions for.
- As a member of the Biomedical Informatics department you will be responsible for investigating, prototyping, and implementing new scientific capabilities and disseminating the latest Bioinformatics, Data Science and Computational Biology research trends and developments throughout the organisation.
We are looking for:
- PhD in bioinformatics, computational biology or related field of research
- Experience (1+ years, preferably industry-based) of analysing biomedical datasets which reveal novel biological insights and support Clinical Development activities such as biomarker discovery and clinical trial design.
- Experience working in the clinical development stage of drug discovery.
- Advanced programmer in at least one language. We have a strong preference for Python, but are also interested in R. Candidates should also be familiar with the language packages that support Bioinformatic and Data Science activities.
- Track record of processing and deriving novel insights from ‘omics datasets and related resources.
- At least one of the following:
- Experience with using biomolecular network based approaches to aid drug discovery or clinical biomarker development e.g. causal reasoning, pathway mapping and functional module detection.
- Experience using precision medicine approaches to identify patient subgroups
- Experience in processing and analysing NGS datasets (such as RNAseq or epigenetic data).
- Experience in data integration, e.g. using network based or ML approaches.
- Experience in designing experiments to generate data and gain insights into the molecular behaviour of cellular assay systems or patient derived tissues.
- Excellent communicator, both verbal and written, with the ability to influence at all levels and across all departments.
- Bonus points for familiarity with some of the technologies we like, which include: Neo4j, GraphQL, MySQL, Kubernetes, Jupyter.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers the Company’s in-house drug pipeline and supports successful collaborations with AstraZeneca, as well as leading research and charitable institutions.